Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study

Table 2 Therapeutic effects in the two groups

Therapeutic effect^a	After induction therapy (n = 118)						After concurrent radiochemotherapy (n = 117)^b		3 months after the treatment (n = 117)
	Nasopharyngeal lesions (%)		Lymph node lesions (%)		Total(%)(nasopharyngeal and lymph node lesions)		After concurrent radiochemotherapy (n = 117)^b		3 months after the treatment (n = 117)
	NPF group (n = 58)	DPF group (n = 60)	NPF group (n = 58)	DPF group (n = 60)	NPF group (n = 58)	DPF group (n = 60)	NPF group (n = 58)	DPF group (n = 59)	NPF group (n = 58)	DPF group (n = 59)
CR	2(3.4)	0(0)	5(8.6)	1(1.7)	2(3.4)	0(0)	39(67.2)	38(64.4)	51(87.9)	50(84.7)
PR	33(56.9)	31(51.7)	42(72.4)	35(58.3)	39(67.2)	37(61.7)	19(32.8)	21(35.6)	7(12.1)	9(15.3)
SD	23(39.7)	29(48.3)	11(19.0)	24(40.0)	17(29.3)	22(36.7)	0(0)	0(0)	0(0)	0(0)
PD	0(0)	0(0)	0(0)	0(0)	0(0)	1(1.7)	0(0)	0(0)	0(0)	0(0)
P	0.446		0.036		0.143		0.499		0.409

^aCR Complete remission, PR Partial remission, SD Stable disease, PD Progressive disease
^b After induction therapy, 1 patient in the DPF group showed distant metastasis and withdrew from the study

ISSN: 1471-2407